One Carbon Therapeutics has been selected to present the MTHFD1/2 project to the International Board of MATWIN on May 10-11 th

by admin
maj 2, 2023

We are excited to discuss our science and program with major pharma leaders.

Rekommenderade artiklar

One-carbon Therapeutics announces oversubscribed private placement financing of SEK 153 million (€13.9 million)

Solna, Sweden, December 1, 2025. One-carbon Therapeutics AB, a clinical-stage

One-carbon Therapeutics AB Announces First Subject Dosed in the ODIN Phase 1/2 Clinical Study of TH9619 in Advanced Solid Tumors

Stockholm, Sweden. November 17th, 2025. One-carbon Therapeutics AB, a clinical-stage biotechnology

One-carbon therapeutics AB management at ESMO to discuss the ODIN clinical phase 1/2 trial with potential clinical sites across Europe

One-carbon therapeutics AB is discussing the ODIN trial with several